IPO
Key Metrics
Market cap
~$1.7B-$2.2B (Sept 2026; sources vary)
As of Sep 2026EstimatedValue Add Pulse research
Total funding
$185M Series A + $382.5M IPO
As of Sep 9, 2026Value Add Pulse research
Company Snapshot
Braveheart Bio is a Biotech company, based in San Francisco, California, USA, founded 2025 by Travis Murdoch. Market cap ~$1.7B-$2.2B (Sept 2026; sources vary) (As of Sep 2026, Value Add Pulse research). Total funding $185M Series A + $382.5M IPO (As of Sep 9, 2026).
Recent changes
- Sep 2026Sep 2026First reported market cap: ~$1.7B-$2.2B (Sept 2026; sources vary)Estimated Value Add Pulse enrichment
- Aug 6, 2026Aug 6, 2026IPO $382.5M at ~$1.27B initial pricing BioPharma Dive
- Aug 6, 2026Aug 6, 2026First reported total funding: $185M Series A + $382.5M IPO BioPharma Dive
- Aug 6, 2026Aug 6, 2026Braveheart Bio Prices Upsized $382.5M IPO on Nasdaq Pulse story
- Aug 5, 2026Aug 5, 2026Braveheart Bio Prices $300M IPO for Heart Drug Pulse story
Earlier changes (6)
- Nov 5, 2025Nov 5, 2025Raised $185M Series A PR Newswire
- Nov 5, 2025Nov 5, 2025New investor: OrbiMed Advisors PR Newswire
- Nov 5, 2025Nov 5, 2025New investor: Enavate Sciences (Patient Square Capital) PR Newswire
- Nov 5, 2025Nov 5, 2025New investor: Forbion Capital Partners PR Newswire
- Nov 5, 2025Nov 5, 2025New investor: Frazier Life Sciences PR Newswire
- Nov 5, 2025Nov 5, 2025New investor: Andreessen Horowitz PR Newswire
Funding History
2 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2026 | IPO | $382.5M | ~$1.27B initial pricing | BioPharma Dive | |
| Nov 5, 2025 | Series A | $185M | — | PR Newswire |
Investors
Latest Pulse
- Aug 10, 2026Biotech IPO Window Closes Its Strongest Week Since SpringBlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.→
- Aug 8, 2026Biotech IPOs Are Pricing Above Range AgainBlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.→
- Aug 6, 2026Braveheart Bio Prices Upsized $382.5M IPO on NasdaqBraveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.→
- Aug 5, 2026Braveheart Bio Prices $300M IPO for Heart DrugBraveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.→
- Jul 14, 2026Two New Biotech IPO Filings Land in One WeekBraveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.→
Coverage Timeline
newest first- Aug 10, 2026IPOBiotech IPO Window Closes Its Strongest Week Since Spring~$972M, 4 deals→
- Aug 8, 2026IPOBiotech IPOs Are Pricing Above Range Again$532.5M combined→
- Aug 6, 2026IPOBraveheart Bio Prices Upsized $382.5M IPO on Nasdaq$382.5M IPO→
- Aug 5, 2026IPOBraveheart Bio Prices $300M IPO for Heart Drug$300M IPO→
- Jul 14, 2026IPOTwo New Biotech IPO Filings Land in One Week2 S-1s, same week→
All Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
IPO
Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined
Biotech IPOs Are Pricing Above Range Again
BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.
BY THE NUMBERS
IPO
Braveheart Bio Prices Upsized $382.5M IPO on Nasdaq
IPO$382.5M IPO
Braveheart Bio Prices Upsized $382.5M IPO on Nasdaq
Braveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.
BRIEF
IPO
Braveheart Bio Prices $300M IPO for Heart Drug
IPO$300M IPO
Braveheart Bio Prices $300M IPO for Heart Drug
Braveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.
IPO
Two New Biotech IPO Filings Land in One Week
IPO2 S-1s, same week
Two New Biotech IPO Filings Land in One Week
Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.
Related Companies
Shared investors
Sources & methodologyshow
Where these figures come from
- PR Newswireprimary source1 fact
- Value Add Pulse researchValue Add VC data2 facts
- BioPharma DiveValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.